Skip to content Report
Our STRAT7 Health team recently ran a pulse survey with GPs and consumers to get some early insights on the implications. What we found was less a story about technology, and more a story about trust.
In the report we explore this potential shift in dynamic and what this means for Pharma brands.
Download the PDF report to understand:
01
ChatGPT Health is not yet widely available. But it’s already widely known about. More than 60% of both consumers and primary care physicians say they are aware of it – but that awareness varies considerably in depth.
Given its infancy, we have focussed on measuring intent and expectation as these are leading indicators of behaviour.
When asked how likely they would be to use ChatGPT Health if or when it becomes available, nearly half of consumers said they were likely or very likely to do so. They also expect to within six months of it launching.
45.5% of consumers say they are likely or very likely to use ChatGPT Health when available, with 21.5% saying they expect to use it within the first month, and almost 47% within six months.
Q: How likely would you be to use ChatGPT Health if/when available? (n=400)
Q: How soon do you expect to use ChatGPT Health, if/when available? (n=400)
02
The anticipated uses of ChatGPT Health span the patient journey, and they cluster around moments that have traditionally been the predominant domain of healthcare professionals.
Understanding medical notes or test results
Seeking a diagnosis
Identifying when to consult a healthcare professional
Preparing for an appointment with an HCP
Supporting treatment decisions
Q: For which purposes would you anticipate using ChatGPT Health if/when available? (n=400)
See the full study findings and implications for pharma leaders:
